CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024

Cytosorbents Corp

FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).
Product gross margin improved to 72% from 70%; expects 75-80% in 2024.
STAR-T trial selected for Breakout Presentation at AATS (April 2024); FDA/Health Canada submission planned for H2 2024.
Ended 2023 with $15.6M cash; cost cuts include 15% RIF; cash runway into Q4 2024.
Entered India partnership with Eris Lifesciences; plan to launch PuriFi pump in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytosorbents Corp reported quarter and year ended December 31, 2023 results: revenue $36.3 million.

Period: quarter and year ended December 31, 2023
Revenue: $36.3 million
Result: reported results

Exact text from the filing

quarter and year ended December 31, 2023 and provides its 2024 outlook. Full Year 2023 Financial Results · 2023 Total Revenue, which includes Product Sales and Grant Income, was $36.3 million versus $34.7 million in 2022, an increase of approximately $1.7 million or 5% · Total product sales were $31.1 million in 2023 versus $29.4 million in 2022, an increase of

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-034674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.